Galderma has announced that the US Food and Drug Administration (FDA) has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21 years. This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.

With the broadest injectable aesthetics portfolio in the industry, this follows the recent US approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands and the chin.

Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalised, natural-looking outcomes that meet diverse patient needs.

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken and aged appearance. These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years resulting in a growing area of aesthetic need.

Galderma is spearheading efforts to address these concerns, including with this latest approval for Restylane Contour, which provides a new option for increasing volume in the temples to help restore balance for a more refreshed and youthful look.

With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Contour enables healthcare professionals to provide precise, customised and safe product placement in line with each patient’s aesthetic goals.

The product is powered by OBT/XpresHAn technology, which integrates into the skin and balances support and flexibility, to provide long-lasting, natural-looking results that move with facial expressions.

The approval is based on clinical results showing that Restylane Contour improved temple hollowing compared with no treatment at three months, with results lasting for up to 18 months, and high investigator and patient (clinical trial participant) satisfaction.